Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

36 results
Display

Meibomian Gland Dysfunction Associated with Bortezomib in a Multiple Myeloma Patient

Yoon DE, Jun RM, Han KE

Purpose: This study reports a case of meibomian gland dysfunction associated with bortezomib, which is a treatment of choice for multiple myeloma. Case summary: A 59‐year‐old female patient presented to our...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis

Hur JY, Yoon SE, Kim D, Choi Jo, Min JH, Kim BJ, Kim JS, Lee JE, Choi JY, Jeon ES, Kim SJ, Kim K

Background Treatment protocols for light chain (AL) amyloidosis have been derived from myeloma treatment. Bortezomib is a key drug used for the treatment of myeloma and AL amyloidosis. We retrospectively investigated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Sweet Syndrome Induced by Bortezomib Rechallenge

Jeong SMG, Kwon CI, Kim CY

  • KMID: 2516144
  • Korean J Dermatol.
  • 2021 May;59(4):299-302.
Sweet syndrome is characterized by fever, tender, erythematous skin lesions, neutrophilia, high levels of serum inflammatory markers, and diffuse mature neutrophil infiltration typically localized to the upper dermis. Various drugs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acute antibody-mediated rejection limited to medullary lesions in following ABO-incompatible living donor kidney transplantation

Kim AY, Cho KH, Park JW, Do JY, Han MH, Kim YJ, Kang SH

Anatomical differences between the renal cortex and medulla may influence inflammatory responses. Owing to the difficulty in diagnosing rejections from the medulla, rejection is usually diagnosed through the cortex. However,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment

Lee SR, Choi H, Lee BH, Kang KW, Yu ES, Kim DS, Park Y, Choi CW, Kim BS, Sung HJ

BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib Treatment for Refractory Antibody-Mediated Rejection Superimposed with BK Virus-Associated Nephropathy during the Progression of Recurrent C3 Glomerulonephritis

Do W, Lee JH, Kim KJ, Han MH, Jung HY, Choi JY, Park SH, Kim YL, Kim CD, Cho JH, Yang Y, Kim M, Hwang I, Kim KY, Yim T, Kim YJ

A 38-year-old man, who underwent a second kidney transplantation (KT), was admitted because of antibody-mediated rejection (AMR) complicated by BK virus-associated nephropathy (BKVAN). He was placed on hemodialysis at the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation

Kim SJ, Jun KW, Hwang JK, Chung BH, Yang CW, Moon IS, Kim JI, Kim MH

BACKGROUND: Bortezomib has been used to treat antibody-mediated rejection (AMR) that usually develops after kidney transplantation (KT). Although it has been used in various clinical situations, it is difficult to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Inhibition of the 26S and 20S Proteasomes by the Site-specific Inhibitors

Woo KM

OBJECTIVE: The study was performed to establish the purification processes of both 26S and 20S proteasomes, also to investigate the inhibitory properties and patterns of two different proteasome inhibitors on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen

Cho HJ, Seo SK, Baek DW, Park SW, Lee YJ, Sohn SK, Lee HS, Lee WS, Lee JH, Kim SH, Moon JH

BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib-induced Histiocytoid Sweet Syndrome

Oh YJ, Lew BL, Sim WY

  • KMID: 2359680
  • Korean J Dermatol.
  • 2016 Nov;54(9):739-743.
Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients

Lee SS, Jung SH, Ahn JS, Kim YK, Cho MS, Jung SY, Lee JJ, Kim HJ, Yang DH

Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens

Hyun SY, Han SH, Kim SJ, Jang JE, Kim Y, Cho H, Lee JY, Cheong JW, Min YH, Song JW, Kim JS

The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens. A total of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Cases of Bortezomib-induced Drug Eruption Presenting as Multiple Plaques on the Trunk

Choe YS, Kim EJ, Na JI

  • KMID: 2245828
  • Korean J Dermatol.
  • 2016 Jan;54(1):47-51.
Bortezomib (Velcade(R)) is proteasome inhibitor that is used as a first-line therapy for multiple myeloma. It can cause gastrointestinal, hematologic, and neuromuscular side effects, and a cutaneous reaction is one...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation

Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH

PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Acute Pancreatitis Caused by Bortezomib in a Patient with Multiple Myeloma

Lim JH, Hwang KB, Lim BH, Jeong YH, Sohn KC, Kim TH

Bortezomib is a proteasome inhibitor used for the treatment of patients with multiple myeloma. Recently, several case reports about acute pancreatitis caused by Bortezomib were published in the international literature....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib inhibits the survival and proliferation of bone marrow stromal cells

Kim HY, Moon JY, Ryu H, Choi YS, Song IC, Lee HJ, Yun HJ, Kim S, Jo DY

BACKGROUND: Bortezomib is widely used for the treatment of multiple myeloma. Bone marrow stromal cells (BMSCs) endow myeloma cells with survival and growth advantages. However, the influence of bortezomib on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib-Based Salvage Chemotherapy in Refractory/Relapsed Multiple Myeloma Patients: A Single Center Experience in Real Clinical Practice

Kim DH, Lee JH, Kim SH, Oh SY, Lee S, Moon SY, Kim HJ

BACKGROUND/AIMS: Bortezomib-based chemotherapy has proven to be an effective salvage regimen for refractory/relapsed multiple myeloma patients in many clinical trials. However, few reports have shown the outcomes and adverse events...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma

Song J, Kim H, Shin S, Kim I, Oh D, Chong S

Bortezomib (Velcade(R)) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Bortezomib on Expression of Inflammatory Cytokines and Survival in a Murine Sepsis Model Induced by Cecal Ligation and Puncture

Han SH, Kim JS, Woo JH, Jeong SJ, Shin JS, Ahn YS, Kim JM

PURPOSE: Although the proteasome inhibitor known as bortezomib can modulate the inflammatory process through the nuclear factor-kappa B signaling pathway, the immunomodulatory effect of pre-incubated bortezomib has not been fully...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation

Yang KS, Jeon H, Park Y, Jo IH, Kim JI, Moon IS, Choi BS, Park CW, Yang CW, Kim YS, Chung BH

This study aimed to investigate the effect of bortezomib in the desensitization and treatment of acute antibody mediated rejection (AAMR) in kidney transplantation. Nine patients who received bortezomib therapy for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr